PPP4R1L Antibody

Basic Research Questions

• What is PPP4R1L and what are its key biological functions?

  PPP4R1L (also known as C20orf192) is classified as a putative serine/threonine-protein phosphatase 4 regulatory subunit 1-like protein with a molecular weight of approximately 49 kDa . While detailed functional characterization is still emerging, it belongs to the family of phosphatase regulatory subunits that typically modulate the activity, localization, and substrate specificity of their catalytic counterparts. The protein likely plays regulatory roles in cellular phosphorylation networks, though specific pathways remain under investigation. Unlike its related protein PPP4R1, which has established roles in cancer progression and immunomodulation, PPP4R1L's precise biological functions require further elucidation .

• What types of PPP4R1L antibodies are available for research applications?

  Several types of PPP4R1L antibodies are commercially available:

  • Polyclonal antibodies raised in rabbits (predominant format)

  • Region-specific antibodies targeting the internal domain, particularly amino acids 191-240

  • Unconjugated primary antibodies optimized for various detection methods

  • Antibodies with validated reactivity against human PPP4R1L, with some showing cross-reactivity to mouse, rat, or monkey orthologs

  These antibodies are typically provided in stabilized formulations containing buffer components such as glycerol (30-50%), sodium azide (0.01-0.02%), and various salts to maintain stability .

• What are the principal applications for PPP4R1L antibodies in experimental research?

  PPP4R1L antibodies have been validated for multiple experimental applications:

  • Western blotting (WB): The most common application, typically using dilutions of 1:500-1:1000

  • Enzyme-linked immunosorbent assay (ELISA): Often utilizing higher dilutions (1:10000)

  • Immunoprecipitation (IP): Used at concentrations of approximately 1:10-1:100 to isolate PPP4R1L and its binding partners

  Some antibodies may also be suitable for immunofluorescence studies, though specific validation data for this application is more limited in the available literature .

• What species reactivity can be expected with PPP4R1L antibodies?

  The species reactivity profile varies among different PPP4R1L antibodies:

  Antibody Catalog	Species Reactivity
  4072708	Human, Mouse, Rat
  ABIN3186544	Human, Monkey
  SAB4502318	Human
  A100123	Human

  When working with non-human samples, it is critical to select antibodies with validated cross-reactivity or perform preliminary validation experiments. Sequence conservation analysis between your species of interest and the immunogen sequence can help predict potential cross-reactivity.

• What are the optimal storage conditions for PPP4R1L antibodies?

  To maintain antibody functionality and prevent degradation:

  • Store at -20°C for long-term preservation (primary recommendation)

  • Aliquot upon first thawing to minimize freeze-thaw cycles

  • For short-term use (1-2 weeks), 4°C storage is generally acceptable

  • Most formulations contain cryoprotectants such as glycerol (30-50%) that prevent damage during freezing

  • Sodium azide (0.01-0.02%) is typically included as a preservative to prevent microbial growth

  The shelf-life at 4°C is highly variable, so dividing into small aliquots (≥20 μl) for freezing is recommended for optimal long-term stability .

Advanced Research Questions

• How can researchers validate the specificity of PPP4R1L antibodies in their experimental systems?

  Comprehensive validation of PPP4R1L antibody specificity requires multiple complementary approaches:

  • Positive controls: Use cell lines with confirmed PPP4R1L expression (e.g., COLO, HUVEC, HepG2, Jurkat, and COS cells)

  • Western blot analysis: Verify single band detection at expected molecular weight (49 kDa)

  • Peptide competition assays: Pre-incubate antibody with immunizing peptide (amino acids 191-240) to confirm signal abolishment

  • Genetic knockdown/knockout: Compare signal in wild-type versus PPP4R1L-depleted samples

  • Cross-reactivity assessment: Test antibody against recombinant PPP4R1 to ensure specificity for PPP4R1L

  • Multiple antibody approach: Use antibodies targeting different epitopes to confirm consistent localization/expression patterns

  This multi-faceted validation strategy minimizes the risk of misinterpreting results due to non-specific binding.

• What is the optimal western blotting protocol for detecting PPP4R1L?

  Based on validated methodologies, the following protocol is recommended:

  1. Sample preparation: Extract proteins using standard lysis buffers (e.g., RIPA buffer with protease inhibitors)

  2. Protein quantification: Use Bradford Protein Assay to standardize loading (approximately 50 μg protein/lane)

  3. Gel electrophoresis: Resolve proteins on 10% polyacrylamide gels

  4. Transfer: Transfer to PVDF membrane using standard procedures

  5. Blocking: Block membrane with appropriate buffer (typically 5% non-fat milk or BSA)

  6. Primary antibody incubation: Apply PPP4R1L antibody at 1:500-1:1000 dilution, incubate overnight at 4°C

  7. Washing: Perform multiple TBST washes

  8. Secondary antibody: Incubate with HRP-conjugated anti-rabbit IgG (most PPP4R1L antibodies are rabbit-derived)

  9. Detection: Visualize using ECL substrate systems

  10. Expected result: Detection of a band at approximately 49 kDa

  Optimization of antibody concentration, incubation time, and blocking conditions may be necessary for different experimental systems.

• How can researchers detect subcellular localization of PPP4R1L using immunofluorescence techniques?

  For immunofluorescence detection of PPP4R1L:

  1. Cell preparation: Culture cells on coverslips and fix with 4% paraformaldehyde

  2. Permeabilization: Use 0.1-0.5% Triton X-100 to allow antibody access to intracellular structures

  3. Blocking: Block with appropriate buffer (e.g., 1-5% BSA) to reduce background

  4. Primary antibody: Incubate with PPP4R1L antibody at approximately 1:500 dilution

  5. Co-staining: Consider co-staining with markers for specific subcellular compartments

  6. Secondary antibody: Use fluorescently-labeled anti-rabbit IgG (e.g., Alexa Fluor conjugates)

  7. Counterstaining: Apply DAPI for nuclear visualization

  8. Mounting: Mount slides with anti-fade mounting medium

  Limited published data suggests PPP4R1L may be present in both cytoplasmic and membrane compartments , but researchers should conduct validation studies in their specific cell types of interest.

• What methodological approaches can identify potential protein interaction partners of PPP4R1L?

  Several complementary techniques can elucidate PPP4R1L's interaction network:

  1. Co-immunoprecipitation (Co-IP):

     • Use PPP4R1L antibodies at IP-optimized dilutions (1:10-1:100)

     • Analyze co-precipitated proteins by mass spectrometry or western blotting

     • Include appropriate controls (IgG control, input samples)

  2. Proximity labeling approaches:

     • Express PPP4R1L fused to biotin ligase (BioID) or APEX2

     • Identify proximal proteins through streptavidin pulldown and mass spectrometry

  3. Yeast two-hybrid screening:

     • Use PPP4R1L as bait to screen cDNA libraries

     • Validate interactions with alternative methods

  4. Competitive endogenous RNA (ceRNA) network analysis:

     • Investigate potential RNA-based regulatory mechanisms, such as the FGD5-AS1–hsa-miR-22-3p–PPP4R1 network identified for the related protein PPP4R1

  These approaches can help elucidate PPP4R1L's functional roles within signaling networks.

• How can researchers troubleshoot inconsistent results when using PPP4R1L antibodies?

  When encountering variable or unexpected results:

  1. Antibody quality assessment:

     • Verify antibody storage conditions and avoid repeated freeze-thaw cycles

     • Check antibody lot-to-lot consistency by requesting validation data

  2. Sample preparation optimization:

     • Ensure complete protein extraction and denaturation

     • Test multiple lysis buffers if PPP4R1L extraction is inefficient

     • Include phosphatase inhibitors if phosphorylation state affects detection

  3. Protocol adjustments:

     • Titrate antibody concentration to determine optimal signal-to-noise ratio

     • Modify blocking conditions to reduce background

     • Extend incubation times or adjust temperatures

  4. Controls and validation:

     • Include positive control samples (e.g., COLO, HUVEC, HepG2 cells)

     • Perform peptide competition assays to confirm signal specificity

     • Consider testing multiple antibodies targeting different epitopes

  5. Technical considerations:

     • Verify equal loading using housekeeping proteins

     • Ensure complete transfer during western blotting

     • Optimize detection sensitivity based on expression level

• What are the key experimental considerations when studying PPP4R1L in cancer research?

  When investigating PPP4R1L in cancer contexts:

  1. Expression analysis across cancer types:

     • While PPP4R1 has established roles in cancer diagnosis and prognosis , PPP4R1L's specific role requires further investigation

     • Compare expression in tumor versus normal tissues using antibody-based methods

     • Use public databases to analyze PPP4R1L mRNA expression across cancer types

  2. Functional studies:

     • Perform knockdown/overexpression experiments to assess effects on cancer cell phenotypes

     • Examine effects on proliferation, migration, invasion, and drug sensitivity

  3. Mechanistic investigations:

     • Assess potential roles in phosphatase regulation pathways

     • Investigate relationships with known cancer-related signaling networks

     • Consider examining drug sensitivity patterns, similar to those documented for the related protein PPP4R1

  4. Clinical correlations:

     • Analyze associations between PPP4R1L expression and clinical outcomes

     • Assess potential as a biomarker or therapeutic target

  The related protein PPP4R1 has been associated with poor prognosis and drug resistance , suggesting PPP4R1L may have similar clinical relevance warranting investigation.

• How can researchers design experiments to study potential post-translational modifications of PPP4R1L?

  To investigate post-translational modifications:

  1. Phosphorylation analysis:

     • Perform immunoprecipitation followed by mass spectrometry

     • Use phospho-specific antibodies in western blotting (if available)

     • Treat samples with phosphatases to observe mobility shifts

  2. Other modifications:

     • Use specific inhibitors of various modification processes

     • Perform mass spectrometry analysis of purified PPP4R1L

     • Look for multiple bands or mobility shifts in western blots

  3. Functional impact:

     • Create site-specific mutants to abolish modification sites

     • Assess effects on localization, protein interactions, and stability

  4. Regulation analysis:

     • Determine stimuli that induce modifications

     • Investigate enzymes responsible for adding/removing modifications

  As a putative regulatory subunit, PPP4R1L likely undergoes post-translational modifications that affect its function, similar to other phosphatase regulatory proteins.

• What methodological approaches can determine the functional significance of PPP4R1L in phosphatase regulation?

  To assess PPP4R1L's role in phosphatase regulation:

  1. Direct interaction studies:

     • Co-immunoprecipitation with catalytic subunits of PPP4 or related phosphatases

     • In vitro binding assays with recombinant proteins

  2. Phosphatase activity assays:

     • Compare phosphatase activity in the presence/absence of PPP4R1L

     • Use phosphatase-specific substrates to measure activity changes

  3. Substrate identification:

     • Perform phosphoproteomic analysis after PPP4R1L manipulation

     • Validate candidate substrates through in vitro dephosphorylation assays

  4. Structure-function analysis:

     • Create deletion mutants to identify critical functional domains

     • Perform domain swapping with related regulatory subunits

  5. Cellular localization:

     • Investigate whether PPP4R1L affects phosphatase localization

     • Examine co-localization patterns through immunofluorescence

• What control samples and experimental validations are essential when using PPP4R1L antibodies?

  Critical controls for PPP4R1L antibody experiments include:

  1. Positive controls:

     • Cell lines with confirmed PPP4R1L expression (COLO, HUVEC, HepG2, Jurkat cells)

     • Recombinant PPP4R1L protein (if available)

  2. Negative controls:

     • Isotype-matched non-specific IgG

     • PPP4R1L-depleted samples (siRNA/shRNA knockdown or CRISPR knockout)

     • Secondary antibody-only controls for immunostaining

  3. Specificity controls:

     • Peptide competition assays using immunizing peptide (amino acids 191-240)

     • Multiple antibodies targeting different epitopes

  4. Technical controls:

     • Loading controls (housekeeping proteins)

     • Transfer efficiency controls

     • Standard curves for quantitative analyses

  These controls ensure reliable and interpretable results while minimizing the risk of artifacts or non-specific signals.

• How should researchers optimize immunoprecipitation experiments using PPP4R1L antibodies?

  For successful PPP4R1L immunoprecipitation:

  1. Sample preparation:

     • Use gentle lysis buffers to preserve protein-protein interactions

     • Include protease and phosphatase inhibitors

     • Pre-clear lysates with protein A/G beads to reduce non-specific binding

  2. Antibody conditions:

     • Use recommended IP dilutions (approximately 1:10-1:100)

     • Consider pre-binding antibody to beads for cleaner results

     • For challenging IPs, consider crosslinking antibody to beads

  3. Incubation parameters:

     • Optimize antibody-sample incubation time (typically 2-16 hours)

     • Perform incubation at 4°C to preserve interactions

     • Use gentle rotation to ensure thorough mixing without damage

  4. Washing and elution:

     • Balance stringency of washes to remove non-specific binding without disrupting specific interactions

     • Consider native elution for functional studies or denaturing elution for maximum recovery

  5. Validation:

     • Confirm successful IP by western blotting a portion of immunoprecipitated material

     • Include IgG control IP and input samples in analysis

  This optimized approach facilitates the study of PPP4R1L and its interacting partners, providing insights into its functional role within protein complexes.